Display options
Cite
Cromwell WC, Otvos JD, Keyes MJ, et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J Clin Lipidol. 2007;1(6):583-92doi: 10.1016/j.jacl.2007.10.001.
Cromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., Sullivan, L., Vasan, R. S., Wilson, P. W., & D'Agostino, R. B. (2007). LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. Journal of clinical lipidology, 1(6), 583-92. https://doi.org/10.1016/j.jacl.2007.10.001
Cromwell, William C, et al. "LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management." Journal of clinical lipidology vol. 1,6 (2007): 583-92. doi: https://doi.org/10.1016/j.jacl.2007.10.001
Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, Wilson PW, D'Agostino RB. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J Clin Lipidol. 2007 Dec;1(6):583-92. doi: 10.1016/j.jacl.2007.10.001. PMID: 19657464; PMCID: PMC2720529.
Copy Download .nbib Format: NLM
Share it on

J Clin Lipidol. 2007 Dec;1(6):583-92. doi: 10.1016/j.jacl.2007.10.001.

LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management.

Journal of clinical lipidology

William C Cromwell, James D Otvos, Michelle J Keyes, Michael J Pencina, Lisa Sullivan, Ramachandran S Vasan, Peter W F Wilson, Ralph B D'Agostino

Affiliations

  1. Division of Lipoprotein Disorders, Presbyterian Center for Preventive Cardiology, Charlotte, NC.

PMID: 19657464 PMCID: PMC2720529 DOI: 10.1016/j.jacl.2007.10.001

Abstract

BACKGROUND: The cholesterol content of LDL particles is variable, causing frequent discrepancies between concentrations of LDL cholesterol and LDL particle number. In managing patients at risk for cardiovascular disease (CVD) to LDL target levels, it is unclear whether LDL cholesterol provides the optimum measure of residual risk and adequacy of LDL lowering treatment.

OBJECTIVE: To compare the ability of alternative measures of LDL to provide CVD risk discrimination at relatively low levels consistent with current therapeutic targets.

METHODS: Concentrations of LDL cholesterol (LDL-C) and non-HDL cholesterol (non-HDL-C) were measured chemically and LDL particle number (LDL-P) and VLDL particle number (VLDL-P) were measured by nuclear magnetic resonance (NMR) in 3066 middle-aged white participants (53% women) without CVD in the Framingham Offspring cohort. The main outcome measure was incidence of first CVD event.

RESULTS: At baseline, the cholesterol content per LDL particle was negatively associated with triglycerides and positively associated with LDL-C. On follow-up (median 14.8 yrs), 265 men and 266 women experienced a CVD event. In multivariable models adjusting for non-lipid CVD risk factors, LDL-P was related more strongly to future CVD in both sexes than LDL-C or non-HDL-C. Subjects with a low level of LDL-P (<25(th) percentile) had a lower CVD event rate (59 events per 1000 person-years) than those with an equivalently low level of LDL-C or non-HDL-C (81 and 74 events per 1000 person-years, respectively).

CONCLUSIONS: In a large community-based sample, LDL-P was a more sensitive indicator of low CVD risk than either LDL-C or non-HDL-C, suggesting a potential clinical role for LDL-P as a goal of LDL management.

References

  1. Am J Epidemiol. 1979 Sep;110(3):281-90 - PubMed
  2. Am J Cardiol. 2003 May 15;91(10):1173-7 - PubMed
  3. Circulation. 2002 Nov 12;106(20):2526-9 - PubMed
  4. Am J Cardiol. 2005 Nov 7;96(9A):3K-13K; discussion 34K-35K - PubMed
  5. Am J Cardiol. 2002 Jul 15;90(2):89-94 - PubMed
  6. Eur Heart J. 2003 Oct;24(20):1843-7 - PubMed
  7. J Lipid Res. 2002 Sep;43(9):1363-79 - PubMed
  8. Clin Chem. 1972 Jun;18(6):499-502 - PubMed
  9. Circulation. 2005 Jun 28;111(25):3465-72 - PubMed
  10. Curr Atheroscler Rep. 2004 Sep;6(5):381-7 - PubMed
  11. Am J Cardiol. 2006 Nov 15;98(10):1363-8 - PubMed
  12. J Intern Med. 2006 Mar;259(3):247-58 - PubMed
  13. Atherosclerosis. 2002 Jan;160(1):41-8 - PubMed
  14. Lancet. 2006 Sep 9;368(9539):919-28 - PubMed
  15. J Clin Pharmacol. 1987 Jul;27(7):475-80 - PubMed
  16. Am J Cardiol. 2002 Oct 17;90(8A):22i-29i - PubMed
  17. Circulation. 2004 Jul 13;110(2):227-39 - PubMed
  18. Am J Cardiol. 2001 Jan 15;87(2):232-4, A9 - PubMed
  19. Clin Chem. 2004 Jul;50(7):1189-200 - PubMed
  20. Am J Cardiol. 2005 Nov 7;96(9A):36K-43K; discussion 34K-35K - PubMed
  21. Am J Cardiol. 2006 Dec 15;98(12):1599-602 - PubMed
  22. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1175-80 - PubMed
  23. Lancet. 2002 Jul 6;360(9326):7-22 - PubMed
  24. Atherosclerosis. 1991 Aug;89(2-3):109-16 - PubMed
  25. Circulation. 2006 Mar 28;113(12):1556-63 - PubMed
  26. J Lipid Res. 1996 Sep;37(9):1924-35 - PubMed
  27. Circulation. 2002 Oct 8;106(15):1930-7 - PubMed
  28. JAMA. 2001 May 16;285(19):2486-97 - PubMed
  29. Arterioscler Thromb Vasc Biol. 2000 Jan;20(1):189-97 - PubMed
  30. Circulation. 2006 Jan 3;113(1):20-9 - PubMed
  31. Lancet. 2003 Mar 1;361(9359):777-80 - PubMed
  32. Clin Lab Med. 2006 Dec;26(4):847-70 - PubMed
  33. Clin Chem. 2005 Dec;51(12):2257-63 - PubMed
  34. Ann Intern Med. 2006 Oct 3;145(7):520-30 - PubMed
  35. JAMA. 2007 Aug 15;298(7):776-85 - PubMed
  36. Clin Chim Acta. 1987 Jun 30;166(1):1-8 - PubMed
  37. Atherosclerosis. 2003 Apr;167(2):243-55 - PubMed
  38. Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):160-7 - PubMed

Publication Types

Grant support